The study was designed as a randomized controlled open trial, and was conducted at the Department of Molecular Gastroenterology and Hepatology at Kyoto Prefectural University of Medicine, Japan.

Changes Clinical Practice Endoscopic mucosal resection (EMR) is a welcome advance as a low-risk alternative for the management of early colonic mucosal lesions. In this multicenter, prospective ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Underwater endoscopic mucosal resection was a safe and effective alternative to conventional ...

Please provide your email address to receive an email when new articles are posted on . Endoscopic mucosal resection followed by radiofrequency ablation had a better safety profile for managing ...

Neuroendocrine tumors (NETs) of the gastrointestinal (GI) tract are a rare and heterogeneous group of malignancies arising from the neuroendocrine cell system. These tumors are more commonly ...

Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic ...

ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial No significant financial ...

For patients with large benign colonic lesions, endoscopic submucosal dissection (ESD) is associated with reduced recurrence at six months compared with endoscopic mucosal resection (EMR), according ...

Compared to minimally invasive surgery, endoscopic submucosal dissection (ESD) represents an advanced, less-invasive endoscopic treatment for early gastrointestinal cancer. ESD has significant ...